Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of once-daily FF/UMEC/VI versus budesonide/formoterol in COPD
2013-003073-10Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone, umeclidinium, vilanterol, budesonide and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough FEV1 at Week 24. Started Jun 2014; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanterolbudesonideformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-003073-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003073-10.